Last updated: April 23, 2026
Which supplier types exist for nifedipine?
Nifedipine is supplied through three practical channels: API manufacturers, formulation/finished-dose contract manufacturers (CDMOs), and trading distributors (API/finished goods). For commercial procurement, the highest-signal path is to anchor on API approvals (DMF/ASMF) and then match to finished-dose manufacturers with validated compression/fill-finish capability for the specific dosage form.
Supplier categories mapped to what buyers typically source
| Supplier type |
What they provide |
Typical buyer use |
| API manufacturer |
Nifedipine API (bulk) |
Build tablets/capsules, generate registration batches |
| CDMO / formulation manufacturer |
Tablets/capsules (often with controlled-release options) |
Commercial or clinical dose manufacture |
| Trading distributor |
API inventory and logistics |
Short lead times, multi-source supply |
Which firms supply nifedipine API or finished dosage products?
Below is a set of commonly listed suppliers and manufacturers in the global value chain for nifedipine. This list is structured for procurement shortlisting: API-first, then finished-dose manufacturing.
API and bulk nifedipine suppliers (global)
| Company |
Supply role |
Notes for sourcing |
| Sino Biopharm |
API supplier |
Commonly listed as a manufacturer/supplier of nifedipine API in trade catalogs |
| BASF |
API/chemical supply |
Large chemical supplier; use is typically via distributor channels unless DMF/registration match is confirmed |
| Cipla |
Finished dose manufacture (brand/generic ecosystem) |
Often supplies markets where nifedipine tablets are marketed; specific product strength/form must be matched |
| Sun Pharma |
Finished dose manufacture (generic ecosystem) |
Check specific strengths and release form in target geography |
| Dr. Reddy’s Laboratories |
Finished dose manufacture |
Depends on market approvals and product portfolio in the target country |
| Teva |
Finished dose manufacture |
Nifedipine is part of cardiovascular generic portfolios in multiple markets |
| Mylan (Upjohn historically) |
Finished dose manufacture |
Portfolio depends on territory; confirm product form and strength |
| Torrent Pharmaceuticals |
Finished dose manufacture |
Confirm strengths and dosage form availability by market |
Procurement implication: API availability and finished-dose availability do not always come from the same entity. If the business goal is to manufacture your own tablets, the API supplier should be selected first based on registration documentation and quality systems, then a CDMO is chosen for the dosage form.
Which dosage forms change supplier selection?
Supplier qualification differs by whether you need immediate-release tablets versus modified-release products.
Nifedipine dosage forms that affect sourcing
- Immediate-release (IR) tablets/capsules
- Modified-release products (extended-release formulations)
- Other solid oral forms (market-dependent)
Why this matters for suppliers: CDMOs and formulation lines must match dissolution specifications and release technology. An IR API line does not automatically map to validated modified-release manufacturing.
How to vet a nifedipine supplier (API or finished dose) fast
For high-stakes R&D or investment decisions, qualification should be evidence-driven. Use the following checklist structure.
1) Quality system and compliance
- Request GMP certificate for the manufacturing site
- Confirm whether the supplier is operating under ICH Q7 (API) or applicable GMP for finished dose
- Verify that the supplier can provide:
- CoA with batch-specific test results
- Specification sheet
- Impurities profile (including key genotoxicity-relevant impurities where applicable)
- Stability protocol and results (for finished doses)
2) Regulatory documentation trail
- For API: check whether the supplier’s site is covered in DMF/ASMF filings for your target markets
- For finished dose: confirm local marketing authorization and whether the product is manufactured under local regulatory oversight (depends on jurisdiction)
3) Manufacturing capability matching your target product
- Dosage form capability:
- IR: tablet compression, coating, packaging readiness
- Modified-release: specific release tech and dissolution strategy
- Scale:
- Phase-appropriate clinical scale capability (small batches)
- Commercial scale capability (long-run consistency)
Which supplier approach minimizes risk for commercial scale?
A low-friction, defensible approach is:
1) API shortlisting based on:
- GMP coverage for the site
- ability to support regulatory filings for the target markets
- batch-to-batch impurity control track record (per CoA)
2) CDMO selection based on:
- demonstrated experience with the exact dosage form (IR vs modified-release)
- validated dissolution and release testing (as applicable)
3) Second-source planning:
- secure a backup API supplier
- keep a backup CDMO for the dosage form
This reduces the operational bottleneck risk where API supply issues block finished-dose manufacturing.
What procurement documents should you require for nifedipine?
At minimum, require these deliverables during supplier qualification.
API qualification package
| Document |
Why it matters |
| CoA for at least 1 representative batch |
Confirms actual release against your target spec |
| API specification sheet |
Confirms identity, purity, assay, impurities, particle-related specs |
| Analytical methods (or method summary) |
Ensures your QC acceptance criteria can be aligned |
| Stability report or stability protocol |
Supports shelf-life and retest period |
| GMP certificate |
Establishes manufacturing compliance |
Finished-dose qualification package
| Document |
Why it matters |
| CoA + batch record summary |
Confirms dissolution and content uniformity compliance |
| Finished product specification |
Aligns with your market requirements |
| Dissolution/release method details |
Ensures comparability and scale transfer |
| Stability protocol and report |
Supports shelf-life commitments |
| GMP certificate for the site |
Confirms manufacturing compliance |
Where do suppliers show up in practice: market-by-market
Nifedipine is widely marketed as a generic cardiovascular drug. Supplier availability differs by territory because authorization and manufacturing sites vary. For business users, the practical steps are:
- Match product strength and release form to the supplier’s registered portfolio in your target country
- Prefer suppliers with a history of supply continuity in that geography
- Use distributor networks only after you confirm:
- the actual manufacturing site
- batch paperwork authenticity
- GMP and CoA traceability
Key Takeaways
- Nifedipine sourcing splits into API manufacturers, CDMOs for tablets/capsules, and distributors; pick API first if you plan to manufacture dosage internally.
- Supplier selection depends heavily on dosage form (immediate-release versus modified-release).
- Qualification should be document-based: GMP, CoA, specs, and (for finished doses) dissolution/release evidence plus stability.
- For procurement risk control, use second-source planning for both API and dosage manufacturing.
FAQs
1) Can one supplier provide both nifedipine API and finished tablets?
Yes, some firms supply both, but many supply only one layer. Procurement should confirm the manufacturing site and registration coverage for each layer.
2) What is the most common failure point when switching nifedipine suppliers?
Inconsistent impurity profiles and/or dissolution performance, especially when switching across dosage forms or release technologies.
3) Is nifedipine API procurement the same as procurement of finished tablets?
No. API specs and stability/retest planning differ from finished-dose dissolution, content uniformity, and release testing.
4) What should I prioritize: price or regulatory alignment?
Regulatory alignment should lead. Price-only selection increases risk of batch rejection, delayed timelines, and revalidation for release and stability.
5) How do I validate that a “supplier” is the actual manufacturer?
Require GMP certificates for the manufacturing site and batch-specific CoA traceability to that site. If the certificate does not match the batch paperwork, it is a red flag.
References
[1] U.S. National Library of Medicine. Nifedipine. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a682864.html
[2] European Medicines Agency (EMA). Public assessment and pharmacovigilance resources for nifedipine-containing products (varies by product). https://www.ema.europa.eu/
[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients. https://www.ich.org/
[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q8/Q9/Q10 general quality system framework (used for alignment). https://www.ich.org/
